For example, fibrinolytic agents, such as Tenecteplase or Urokinase, that target plasmin (beta [95% CI] = −0.21 [−0.19 to −0.23], p = 3.83 × 10−94, UniProt: P00747) have been described to be differentially effective in female and male patients in post stroke therapy21. Here, PLG is linked to stroke disorder.